Additionally, targeting XIAP together with BCL‐2 was recently suggested as promising treatment for aggressive AML subtypes, where certain mutations, karyotypes and TP53 transcriptional activity correlated with response (Hashimoto et al, 2021). The gene discussed is XIAP; the disease is acute myeloid leukemia.